Xoma Royalty CORP

Ligand Pharmaceuticals Incorporated has finalized its acquisition of XOMA Royalty Corporation, with XOMA Royalty stockholders receiving $39.00 per share in cash and a Contingent Value Right.

XOMA Royalty Corporation expects its acquisition by Ligand Pharmaceuticals to close on July 14, 2026, and has initiated the full redemption of its outstanding preferred stock.

XOMA Royalty Corp stockholders approved new equity incentive plans and the board adopted bylaw amendments regarding forum selection and Nevada statutes.

Xoma Royalty Corporation announced an amendment to its merger agreement with Ligand Pharmaceuticals Incorporated, adding a new holding company as a party to the transaction.

XOMA Royalty Corporation has finalized its acquisition of Generation Bio Co., integrating its assets and contingent value rights.

Ligand Pharmaceuticals announced its definitive agreement to acquire XOMA Royalty Corporation for approximately $739 million in cash, aiming to expand its royalty portfolio and accelerate profit growth.

XOMA Royalty Corporation reports significant net income growth and strategic acquisitions in Q3 2025, driven by increased royalty and milestone payments.

XOMA Royalty Corporation announced significant revenue growth and improved operating cash flow for the first half of 2025, driven by key milestone achievements and strategic portfolio expansion.

XOMA Royalty Corporation announces a net income of $2.4 million for the first quarter of 2025, driven by increased revenue from purchased receivables and strategic acquisitions.

XOMA Royalty Corporation's Q3 2024 results reflect a net loss, impacted by the Kinnate acquisition and royalty asset impairments, while also showing increased income from purchased receivables.

XOMA Royalty Corporation reports a net income of $16.0 million for the second quarter of 2024, driven by the acquisition of Kinnate and changes in fair value of assets.

XOMA Corporation's first quarter 2024 results show a net loss, but also highlight strategic acquisitions and a strong cash position.

XOMA Royalty Corporation's 2024 results reflect strategic portfolio expansion through acquisitions and royalty stream management, despite a net loss.

XOMA Corporation outlines the details of its common and preferred stock, including dividend rights, voting rights, and liquidation preferences, in a recent SEC filing.

Bvf Partners L P/Il and 9 others reported changes in beneficial ownership of XOMA Royalty Corp common stock on July 14, 2026.

Maricel Perea Montano, Chief Legal Officer of XOMA Royalty Corp, reported multiple transactions in common stock on July 14, 2026.

Joseph M Limber, a Director of XOMA Royalty Corp, reported multiple transactions in common stock on July 14, 2026.

Barbara Kosacz, a Director of XOMA Royalty Corp, reported multiple transactions in common stock on July 14, 2026.

Jack L Wyszomierski, a Director of XOMA Royalty Corp, reported multiple transactions in common stock on July 14, 2026.

Owen Hughes, Chief Executive Officer and a Director of XOMA Royalty Corp, reported multiple transactions in common stock on July 14, 2026.

XOMA Royalty Corporation calls a May 21, 2026 virtual annual meeting to elect directors, ratify Deloitte, expand its long‑term incentive plan by 425,000 shares, adopt a 500,000‑share ESPP, and hold a Say‑on‑Pay vote.

XOMA Royalty Corporation is asking stockholders to vote on proposals including reincorporation from Delaware to Nevada, amendments to the bylaws, and approval of an amended long-term incentive plan at the annual meeting on May 21, 2025.

XOMA Corporation's stockholders are being asked to vote on the election of directors and the ratification of Deloitte & Touche LLP as the independent auditor at the upcoming annual meeting on May 15, 2024.

XOMA Corporation schedules its annual stockholders meeting for May 15, 2024, to elect directors and ratify the selection of its independent accounting firm.

XOMA Royalty Corp. announced the completion of its merger with Ligand Pharmaceuticals Incorporated, resulting in the cessation of beneficial ownership for Biotechnology Value Fund L.P. and its affiliates.

BVF Partners converted Series X Preferred Stock into 5,003,000 shares of XOMA Royalty Corp common stock, increasing their beneficial ownership to 43.3%.

Ligand Pharmaceuticals has entered into a definitive agreement to acquire XOMA Royalty Corporation in an all-cash transaction valued at $39.00 per share plus contingent value rights.

XOMA Royalty Corp. announces a merger agreement with Ligand Pharmaceuticals Inc., with key shareholders entering a support agreement to vote in favor of the transaction.

Biotechnology Value Fund and its affiliates have filed an amended Schedule 13D, disclosing a reduction in their beneficial ownership of XOMA Royalty Corp common stock to 21.6% following a private sale of 392,723 shares at $27.10 per share.

Biotechnology Value Fund (BVF) and its affiliated entities have significantly reduced their beneficial ownership in XOMA Royalty Corp, selling over 650,000 shares in a private transaction.

Vanguard Capital Management has reported a beneficial ownership of 571,823 shares, representing 3.23% of the outstanding common stock in XOMA Royalty Corp.

Woodline Partners LP has reported beneficial ownership of 640,001 shares, representing 5.4% of XOMA Royalty Corp's common stock as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 5.15% of XOMA Royalty Corp's common stock as of March 31, 2026.

The Vanguard Group filed an amended Schedule 13G for XOMA Royalty Corp, reporting zero beneficial ownership following an internal realignment.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a combined beneficial ownership of 10.2% in XOMA Royalty Corporation's common stock as of February 27, 2026.

Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., reported a combined beneficial ownership of 13.7% in XOMA Royalty Corp common stock.